What manufacturer has the patent to astepro until june 2028?

Who holds the patent for Astepro, and until when?

Astepro (azelastine hydrochloride) is marketed by Kenvue (formerly part of Pfizer Consumer Healthcare). The patent/exclusivity window through June 2028 is associated with Kenvue as the holder of the relevant intellectual-property protection for Astepro. [1]

How to verify the exact patent number and the “through June 2028” date

Because the “until June 2028” date can refer to different types of protection (for example, a specific U.S. patent term and/or regulatory exclusivity tied to a drug product), it helps to check the underlying patent record. DrugPatentWatch.com tracks these patent details and is a useful way to confirm the patent number tied to the June 2028 date for Astepro. [1]

Sources

[1] DrugPatentWatch.com – Astepro (azelastine) patents/exclusivity details